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according to the AIT’s criteria could result in better clinical outcomes with little 
impact on the annual budget.
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Objectives: To quantify the number and costs of relapses avoided over 2 
years in the first-line treatment of RRMS based on the findings of the Cochrane 
report. MethOds: An Excel-based financial model estimated the relapses and costs 
incurred by a hypothetical cohort of 1000 RRMS patients treated with first-line 
disease-modifying drugs (DMDs). The modelled cohort evaluated the consequences 
of treatment with subcutaneous (SC) interferon beta-1a versus intramuscular 
(IM) interferon beta-1a, as this was the only comparison whose data quality was 
assessed as ‘high’ by the Cochrane Review (Filippini et al., 2013). Risk of relapse 
was based on the 2-year data from the Cochrane Review network meta-analysis. 
The analysis was performed from a US payer perspective. The cost of a relapse was 
sourced from Panitch et al., 2005, and adjusted to 2012 US dollars. Net annual cost 
of therapy was based on wholesale acquisition cost. Given the model’s short time 
horizon, disability-related costs were not included as these tend to be an important 
economic driver only over the long-term progression of the disease. In order to test 
how variability in the model’s inputs might impact the analysis’ results, two-way 
sensitivity analyses were performed based on the reported 95% risk of relapse cred-
ible intervals for SC interferon beta-1a and IM interferon beta-1a. Results: In a 
hypothetical cohort of 1000 RRMS patients, treatment with SC interferon beta-1a 
is expected to result in the avoidance of 173 (sensitivity analysis range: -20 to 399) 
relapses versus IM interferon beta-1a over 2 years. Assuming a direct cost of relapse 
of $5141, this represents a savings of $890,212 (sensitivity analysis range: -$102,138 
to $2,052,934) versus IM interferon beta-1a. cOnclusiOns: Subcutaneous inter-
feron beta-1a is likely to result in fewer relapses and lower direct costs of relapse 
versus IM interferon beta-1a over a 2-year period treatment.
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Objectives: Gaucher disease (GD), a lysosomal storage disorder caused by muta-
tions in the gene encoding the enzyme glucocerebrosidase, requires life-long treat-
ment with enzyme replacement therapy (ERT). Currently available ERTs include 
imiglucerase, velaglucerase alfa, and taliglucerase alfa. Taliglucerase alfa is the first 
plant cell-expressed beta-glucocerebrosidase ERT approved for adults with type 
1 GD. The purpose of this analysis was to model the potential budget impact of 
taliglucerase alfa therapy for GD in the United States. MethOds: A hypothetical 
budget impact model analysis was performed, based on total estimated number of 
GD patients treated, treatment costs, and estimated treatment distribution of each 
ERT. Costs in USD ($) per 200-unit vial were based on wholesale acquisition costs on 
ReadyPrice and Medi-Span databases. Annual costs were calculated using number 
of vials required. Actual cost savings may vary with factors beyond drug acquisition 
costs (eg, rebate programs) and may not reflect actual costs paid. Results: The 
estimated number of GD patients treated with ERT in the United States was 3,000. 
Drug costs for 200 units of ERT were: taliglucerase alfa–$595, velaglucerase alfa–$675, 
and imiglucerase–$793. Annual costs/patient were estimated at $328,440, $372,600, 
and $437,736 for taliglucerase alfa, velaglucerase alfa, and imiglucerase, respectively. 
Switching 50 patients to taliglucerase alfa, assuming same market share as national 
average, could save up to $4 million annually. The US health care system could 
save ~$100,000/patient annually if patients were switched to taliglucerase alfa. A 
20% increase in the number of patients receiving taliglucerase alfa could translate 
to an overall savings of ~$46 million annually. cOnclusiOns: Taliglucerase alfa 
has the potential to provide a cost-saving alternative to other ERTs. This study was 
sponsored by Pfizer. Editorial support was provided by Peloton Advantage, LLC with 
funding from Pfizer.
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Objectives: Souvenaid® is a medical food - an enriched nutritional formula - that 
contains specific nutrients reported to be deficient in patients with Alzheimer’s 
Disease (AD) and that are important in cognitive function, synapse formation and 
function. Clinical studies demonstrate that dietary management with Souvenaid® 
for 12 to 24 weeks results in a significant improvement in memory in patients with 
early AD. This study aims to estimate the budget impact of Souvenaid® for the 
dietary management of mild AD according to SUS perspective. MethOds: An age 
related incidence of AD approach was used. Population size, according to different 
age categories, was derived from Brazilian statistics (IBGE) and combined to estimate 
the number of patients per age stratum. Average cost of AD was derived from a 
7-state Markov model developed to estimate the effect of Souvenaid® for mild AD 
versus no dietary management (NDM) of mild AD and combined with demographic 
data in each age stratum. Only direct costs, obtained from a public hospital in 
Brazil, were considered. The difference between Souvenaid® group and NDM was 
the 5-year budget impact estimated for SUS. Results: Considering a market pen-
etration of 10%, 13%, 15%, 17% and 20% each year, the estimated number of patients 
under Souvenaid® treatment is 11.002, 15.733, 19.969, 24.894 and 32.216, respectively, 
for years 1-5. Compared to NDM, the inclusion of Souvenaid® in the protocol of mild 
Objectives: Triptan medication use is contraindicated in adults with migriane who 
have cardiovascular disease or cardiovascular (CV) risk factors (i.e., hypertension, 
diabetes, hyperlipidemia, and obesity). The objective of this study is to compare 
Triptan use among Migraineurs with and without cardiovascular disease (CVD) or 
CVD risk factors such as those with diabetes, hypertension, hyperlipidemia, and 
obesity. MethOds: This is a retrospective cross-sectional study using data from 
2009 and 2011 Medical Expenditure Panel Survey (MEPS). The study sample con-
sisted of adults with migraine aged 22-64 years and alive during the calendar years 
(N = 1,142). Chi-square tests were used to compare rates of Triptan use among 
adults with and without CVD/CVD risk factors. Multiple logistic regressions were 
used to compare the likelihood of Triptan use among Migraineurs with and without 
CVD/CVD risk factors. All analyses accounted for the complex survey design of the 
MEPS. Results: Among adult Migraineurs, 26.3% with CVD/CVD risk and 34.3% 
without CVD reported Triptan medication use. After controlling for gender, age, 
race/ethnicity, marital status, education, employment, income level, insurance and 
medication coverage, perceived physical and mental health, current smoking and 
exercise, adults with CVD/CVD risk were less likely to use Triptans compared to 
adults without CVD/CVD risk. (Adjusted Odds Ratio: 0.59, 95% Confidence Interval 
[0.43-0.82]). cOnclusiOns: Although adults with CVD/CVD risk were less likely 
to report Triptan use compared to adults without CVD/CVD risk, nearly 26% of 
Migraineurs with CVD/CVD risk reported Triptan use. The study findings suggest 
that Triptan medication use among adults with CVD/CVD risk is not consistent with 
recommended clinical guidelines.
NeurOlOgIcAl DIsOrDers – cost studies
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Objectives: To estimate the budget impact of adding delayed-release dimethyl 
fumarate, a new oral drug indicated for the treatment of relapsing forms of mul-
tiple sclerosis (MS) to a managed care formulary in the US. MethOds: An Excel 
model was developed to compare the drug-related costs of the current mix of treat-
ments with the costs of an estimated treatment mix including delayed-release 
dimethyl fumarate for a managed care organization (MCO) with 1,000,000 covered 
lives. The number of people with relapsing forms of MS was estimated using pub-
lished prevalence data. Market share of delayed-release dimethyl fumarate was 
assumed to increase from 10% in 2013 to 25% in 2017 taken proportionately by 
market shares from all other DMTs. Drug costs included acquisition costs adjusted 
by patient payments and dispensing fees as well as administration, monitoring 
and adverse event costs. Annual relapse treatment costs were estimated using the 
relative risk reduction of a relapse for each DMT derived using a mixed-treatment 
comparison analysis. A one-way sensitivity analysis was performed. Results: 
The estimated budget impact of adding delayed-release dimethyl fumarate to 
the formulary was negative for the first 5 years: in 2014, with a market share of 
13.0%, the estimated budget decrease was 0.29% of the total annual costs for 
DMT-related and relapse treatment costs and a decrease of $0.011 per member 
per month (PMPM); in 2017, with a market share of 25.0%, the estimated budget 
decrease was 0.50% of the total annual costs and a decrease of $0.018 PMPM. 
Sensitivity analyses showed that the model was most sensitive to the acquisi-
tion costs of delayed-release dimethyl fumarate. cOnclusiOns: Under model 
assumptions for market shares, adding delayed-release dimethyl fumarate to the 
MCO formulary would result in a small decrease in MCO costs for patients with 
relapsing forms of MS.
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Objectives: In 2013, the Amyloid Imaging Taskforce (AIT) proposed that individuals 
with unexplained mild-cognitive impairment, possible AD, and early-onset demen-
tia are potentially appropriate for amyloid PET in the diagnosis of AD and other 
forms of dementia. This analysis quantified the budgetary impact of using amyloid 
PET according to the AIT’s criteria from the US payer perspective. MethOds: An 
Excel-based model was developed for this analysis. The model projects the number 
of patients eligible for amyloid PET over a 3-year time horizon and calculates the 
incremental cost of using amyloid PET by considering direct medical resource uses 
for diagnostic work-up, dementia medications, and dementia care for patients stay-
ing in communities or institutions. Amyloid PET’s cost could be potentially offset by 
reducing diagnostic work-up time and resources use, unnecessary dementia treat-
ments and delaying disease progression and time to institutional care. The model 
was mainly populated with data from claims data analysis (Truven MarketScan® 
2007–2012) and a survey of 75 dementia practitioners in the US, supplemented 
with data from literature, public databases, and assumptions. All costs were esti-
mated in 2013 dollars. Results: Assuming an uptake of 5% incrementally each 
year, using amyloid PET increased the total cost by about $560,000 to $1,140,000 
per 1 million covered lives over 3 years (or $0.016 to $0.032 per member per month) 
when amyloid PET’s cost was set between $2,500 and $6,000 per scan. Amyloid PET’s 
cost was partially offset by reductions in diagnostic work-up time and resources 
use and costs of institutional care due to more timely and accurate diagnosis and 
treatment. These results were most sensitive to variations in the cost of amyloid 
PET and time horizon. cOnclusiOns: Using amyloid PET in the diagnosis of AD 
